Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT06165809
Other study ID # TQB3015-I-01
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date December 2023
Est. completion date May 2024

Study information

Verified date December 2023
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is divided into two stages: dose escalation and dose extension, including a single dose and a multiple dose clinical study. This is a single-center, open, non randomized, single arm study to the safety and tolerability of TQB3015 tables in patients with advanced malignant cancer.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study; - Age: 18 to 75 years old; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; - Advanced malignant tumors confirmed by tissue or cellular pathology and the routine standard treatment was ineffective or lack of effective treatment plans, or patients cannot tolerate the standard treatment; - Has at least one assessable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria; - The main organs function well; - Female patient had no plans to become pregnant and voluntarily took effective contraceptive measures during the study period and until at least 6 months after the last dose of study drug. Exclusion Criteria: - Concomitant disease and medical history: 1. There were other malignant tumors occured within 3 years before the first dose of study drug. 2. Has multiple factors affecting oral medication; 3. Unalleviated toxicity = grade 1 according to CTCAE v5.0 due to any previous therapy, excluding hair loss; 4. Major surgical treatment, open biopsy and obvious traumatic injury were performed within 28 days before the study, or have not fully recovered from previous surgery, or are expected to require major surgical surgery during the study period; 5. Arteriovenous thrombotic events occurred within 6 months before the first dose, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism; 6. Have a history of psychotropic drug abuse and can not quit or have mental disorders; 7. Subjects with any severe and/or uncontrolled disease including active hepatitis, immunodeficiency; - Tumor-related symptoms and treatment: 1. Has known symptomatic central nervous system metastases and/or cancerous meningitis; 2. Have received surgery, chemotherapy, radiation therapy (2 weeks for brain radiation therapy) or other anti-cancer therapies within 4 weeks prior to the first dose. 3. Thoracic/abdominal/pericardial effusion with clinical symptoms or requiring repeated drainage, or drainage for the purpose of receiving treatment within one month after receiving the investigational drug for the first time. 4. Has Participated in other clinical trials within 4 weeks before first dose. - According to the judgement of the investigators, there are other factors that may lead to the termination of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TQB3015 tablets
TQB3015 is a protein inhibitor

Locations

Country Name City State
China Harbin Medical University Cancer Hospital Harbin Heilongjiang

Sponsors (1)

Lead Sponsor Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose Limiting Toxicity (DLT) DLT will be defined as toxicities that meet pre-defined severity criteria according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 toxicity, and assessed as having a suspected relationship to study drug that occurred from the first dose to the end of the first treatment cycle. At the end of Cycle 1 (Day 21).
Primary Maximum tolerated dose (MTD) MTD was defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients. At the end of Cycle 1 (Day 21).
Primary Recommended Phase II Dose (RP2D) DLT describes side effects of a drug or other treatment that are serious enough to evaluate RP2D of TQB3015 tablets in adult patients with Advanced Malignant Cancer. Baseline up to 24 months
Primary Incidence of abnormal clinical laboratory Incidence of participants with clinical laboratory abnormalities 30 days after the last administration.
Secondary Adverse events (AE) The occurrence of all adverse events (AE). 30 days after the last administration.
Secondary Serious adverse events (SAE) The occurrence of all serious adverse events (SAE). 30 days after the last administration.
Secondary Time to reach maximum (peak) plasma concentration (Tmax) To characterize the pharmacokinetics of TQB3015 by assessment of time to reach maximum plasma concentration after single and multiple dosing. Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.
Secondary Peak concentration (Cmax) The maximum observed plasma concentration of study drug. Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.
Secondary Half-life (t1/2) The time required for half of the drug to be eliminated from the plasma. Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.
Secondary Area under the concentration-time curve from zero to infinity (AUC0-8) To characterize the pharmacokinetics of TQB3015 by assessment of area under the plasma concentration time curve from 0 extrapolated to infinity. Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.
Secondary Area under the concentration-time curve from zero to last observation (AUC [0-t]) To characterize the pharmacokinetics of TQB3015 by assessment of area under the plasma concentration time curve from the first dose to a certain time point. Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.
Secondary Apparent clearance (CL/F) Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.
Secondary Apparent volume of distribution (Vd/F) Apparent volume of distribution of the TQB3015 in plasma. Pre-dose, at 0.5, 1, 2, 3,4, 6, 8, 11, 24, 48, 72 hours after single administration dose. Pre-dose on Cycle 1 Day 7,Cycle 1 Day 14, Cycle 1 Day21; 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours after-dose on Cycle 1 Day 21. Each cycle is 21 days.
Secondary Objective response rate (ORR) The percentage of patients with complete response (CR) and/or partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03671226 - Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center N/A
Recruiting NCT05048160 - A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm Phase 1/Phase 2
Active, not recruiting NCT03287492 - RCT of QPS vs General Information Sheet N/A
Recruiting NCT01549067 - The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey N/A
Recruiting NCT04119037 - Cordotomy in Reducing Pain in Patients With Advanced Cancer N/A
Recruiting NCT04067336 - First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Completed NCT02823652 - Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer N/A
Completed NCT00244972 - Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer Phase 1
Recruiting NCT06297642 - TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. Phase 1
Active, not recruiting NCT01582191 - Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Phase 1
Active, not recruiting NCT03856060 - Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits N/A
Completed NCT04186884 - Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
Completed NCT02583269 - Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery Phase 1
Withdrawn NCT03868423 - Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Phase 2
Terminated NCT02940223 - Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer Phase 2
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Active, not recruiting NCT03021486 - Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer Phase 2/Phase 3
Recruiting NCT03203525 - Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Phase 1
Completed NCT01624766 - Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Phase 1